Prognostic Revalidation of RANO Categories for Extent of Resection in Glioblastoma: a Reconstruction of Individual Patient Data

Overview

Journal J Neurooncol

Publisher Springer

Date 2025 Feb 24

PMID 39992571

Authors

Johannes Wach

Martin Vychopen

Erdem Guresir

Affiliations

Soon will be listed here.

Abstract

Background: The RANO classification for glioblastoma defines resection categories based on volumetric tumor assessments, aiming to standardize outcomes related to extent of resection (EOR). This study revalidates the prognostic impact of RANO classes by reconstructing individual patient data (IPD).

Methods: A systematic review and meta-analysis were performed, including three studies comprising 580 glioblastoma patients. Included studies reported or allowed conversion to RANO classes for glioblastoma resection extent, with detailed OS data and numbers at risk. Overall survival (OS) data were extracted from Kaplan-Meier survival curves, and IPD were reconstructed using Digitizelt and the R package IPDfromKM. Survival analyses were conducted using Kaplan-Meier estimates and Cox regression models.

Results: Median follow-up was 15.6 months (IQR: 10.1-28.8). Patients undergoing supramaximal resection (RANO class 1, n = 163) had the highest median OS (35.6 months; 95% CI: 30.9-40.4), significantly outperforming non-class 1 resections (median OS: 13.9 months; 95% CI: 13.0-14.7; p < 0.001). Subgroup analysis revealed superior OS for class 2a (19.0 months) over class 2b (14.1 months; p < 0.001), while class 3 and 4 resections demonstrated progressively poorer outcomes. Hazard ratios consistently favored class 1 versus all other classes (HR: 0.28; 95% CI: 0.23-0.37).

Conclusions: Supramaximal (class 1) resection provides a significant survival benefit in glioblastoma, underscoring its critical role in surgical management. The RANO classification stratifies resection outcomes effectively, supporting its use as a prognostic tool. These findings advocate for resection strategies targeting maximal tumor removal.

References

Wen P, Weller M, Quant Lee E, Alexander B, Barnholtz-Sloan J, Barthel F . Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020; 22(8):1073-1113. PMC: 7594557. DOI: 10.1093/neuonc/noaa106. View

Karschnia P, Gerritsen J, Teske N, Cahill D, Jakola A, van den Bent M . The oncological role of resection in newly diagnosed diffuse adult-type glioma defined by the WHO 2021 classification: a Review by the RANO resect group. Lancet Oncol. 2024; 25(9):e404-e419. DOI: 10.1016/S1470-2045(24)00130-X. View

Gerritsen J, Zwarthoed R, Kilgallon J, Nawabi N, Versyck G, Jessurun C . Impact of maximal extent of resection on postoperative deficits, patient functioning, and survival within clinically important glioblastoma subgroups. Neuro Oncol. 2022; 25(5):958-972. PMC: 10158118. DOI: 10.1093/neuonc/noac255. View

Altieri R, Broggi G, Certo F, Pacella D, Cammarata G, Maione M . Anatomical distribution of cancer stem cells between enhancing nodule and FLAIR hyperintensity in supratentorial glioblastoma: time to recalibrate the surgical target?. Neurosurg Rev. 2022; 45(6):3709-3716. DOI: 10.1007/s10143-022-01863-8. View

Karschnia P, Young J, Dono A, Hani L, Sciortino T, Bruno F . Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group. Neuro Oncol. 2022; 25(5):940-954. PMC: 10158281. DOI: 10.1093/neuonc/noac193. View

Haddad A, Young J, Morshed R, Berger M . FLAIRectomy: Resecting beyond the Contrast Margin for Glioblastoma. Brain Sci. 2022; 12(5). PMC: 9139350. DOI: 10.3390/brainsci12050544. View

Stewart L, Clarke M, Rovers M, Riley R, Simmonds M, Stewart G . Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015; 313(16):1657-65. DOI: 10.1001/jama.2015.3656. View

Ma L, Wang Y, Yang Z, Huang D, Weng H, Zeng X . Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?. Mil Med Res. 2020; 7(1):7. PMC: 7049186. DOI: 10.1186/s40779-020-00238-8. View

Wei Y, Royston P . Reconstructing time-to-event data from published Kaplan-Meier curves. Stata J. 2018; 17(4):786-802. PMC: 5796634. View

10.

Liu N, Zhou Y, Lee J . IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021; 21(1):111. PMC: 8168323. DOI: 10.1186/s12874-021-01308-8. View

11.

Tropeano M, Raspagliesi L, Bono B, Baram A, Rossini Z, Franzini A . Supramaximal resection: retrospective study on IDH-wildtype Glioblastomas based on the new RANO-Resect classification. Acta Neurochir (Wien). 2024; 166(1):196. DOI: 10.1007/s00701-024-06090-2. View

12.

Park Y, Choi K, Foltyn-Dumitru M, Brugnara G, Banan R, Kim S . Incorporating Supramaximal Resection into Survival Stratification of IDH-wildtype Glioblastoma: A Refined Multi-institutional Recursive Partitioning Analysis. Clin Cancer Res. 2024; 30(21):4866-4875. DOI: 10.1158/1078-0432.CCR-23-3845. View

13.

Baik S, Kim S, Na Y, Cho J . Supratotal Resection of Glioblastoma: Better Survival Outcome than Gross Total Resection. J Pers Med. 2023; 13(3). PMC: 10053695. DOI: 10.3390/jpm13030383. View

14.

Jackson C, Choi J, Khalafallah A, Price C, Bettegowda C, Lim M . A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma. J Neurooncol. 2020; 148(3):419-431. DOI: 10.1007/s11060-020-03556-y. View

15.

Roder C, Stummer W, Coburger J, Scherer M, Haas P, von der Brelie C . Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial. J Clin Oncol. 2023; 41(36):5512-5523. PMC: 10730068. DOI: 10.1200/JCO.22.01862. View

16.

Drexler R, Schuller U, Eckhardt A, Filipski K, Hartung T, Harter P . DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients. Neuro Oncol. 2022; 25(2):315-325. PMC: 9925709. DOI: 10.1093/neuonc/noac177. View

17.

Gerritsen J, Young J, Chang S, Krieg S, Jungk C, van den Bent M . SUPRAMAX-study: supramaximal resection versus maximal resection for glioblastoma patients: study protocol for an international multicentre prospective cohort study (ENCRAM 2201). BMJ Open. 2024; 14(4):e082274. PMC: 11086386. DOI: 10.1136/bmjopen-2023-082274. View

18.

Hirono S, Ozaki K, Kobayashi M, Hara A, Yamaki T, Matsutani T . Oncological and functional outcomes of supratotal resection of IDH1 wild-type glioblastoma based on C-methionine PET: a retrospective, single-center study. Sci Rep. 2021; 11(1):14554. PMC: 8282858. DOI: 10.1038/s41598-021-93986-z. View

19.

Luque L, Skogen K, MacIntosh B, Emblem K, Larsson C, Bouget D . Standardized evaluation of the extent of resection in glioblastoma with automated early post-operative segmentation. Front Radiol. 2024; 4:1357341. PMC: 11150796. DOI: 10.3389/fradi.2024.1357341. View

20.

Brown N, Ottaviani D, Tazare J, Gregson J, Kitchen N, Brandner S . Survival Outcomes and Prognostic Factors in Glioblastoma. Cancers (Basel). 2022; 14(13). PMC: 9265012. DOI: 10.3390/cancers14133161. View